Technical Analysis for NAMS - NewAmsterdam Pharma Company N.V.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Centerline Cross | Bearish | 1.01% | |
Stochastic Reached Oversold | Weakness | 1.01% | |
Multiple of Ten Bearish | Other | 1.01% | |
Oversold Stochastic | Weakness | 1.01% | |
20 DMA Resistance | Bearish | -2.39% | |
50 DMA Resistance | Bearish | -2.39% | |
Inside Day | Range Contraction | -2.39% | |
Gapped Up | Strength | -2.39% | |
50 DMA Resistance | Bearish | -0.99% | |
Fell Below 20 DMA | Bearish | -0.99% |
Alert | Time |
---|---|
Up 3% | about 3 hours ago |
Up 2% | about 3 hours ago |
Up 1% | about 3 hours ago |
Down 3% | about 24 hours ago |
Fell Below Lower Bollinger Band | about 24 hours ago |
Get a Trading Assistant
- Earnings date: 05/06/2024
NewAmsterdam Pharma Company N.V. Description
NewAmsterdam is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients. Results from NewAmsterdam’s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10 mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam was founded in 2019 by the venture capital firm Forbion and John Kastelein, Chief Scientific Officer of the NewAmsterdam, and closed a $196 million (€160 million) Series A financing in January 2021 led by Forbion, Morningside Ventures and Ascendant BioCapital. In June 2022, NewAmsterdam entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe, while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Venture Capital Cardiology Metabolic Disease Lipoprotein Pyridines Low Density Lipoprotein Niacin Alzheimer’s Disease Statin Therapy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 26.2926 |
52 Week Low | 5.6326 |
Average Volume | 181,739 |
200-Day Moving Average | 14.75 |
50-Day Moving Average | 21.33 |
20-Day Moving Average | 21.29 |
10-Day Moving Average | 21.41 |
Average True Range | 1.27 |
RSI (14) | 39.39 |
ADX | 16.68 |
+DI | 12.35 |
-DI | 20.93 |
Chandelier Exit (Long, 3 ATRs) | 19.21 |
Chandelier Exit (Short, 3 ATRs) | 22.55 |
Upper Bollinger Bands | 23.06 |
Lower Bollinger Band | 19.52 |
Percent B (%b) | 0.08 |
BandWidth | 16.65 |
MACD Line | -0.10 |
MACD Signal Line | 0.10 |
MACD Histogram | -0.1958 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 22.12 | ||||
Resistance 3 (R3) | 22.29 | 21.69 | 21.73 | ||
Resistance 2 (R2) | 21.69 | 21.10 | 21.60 | 21.61 | |
Resistance 1 (R1) | 20.75 | 20.74 | 20.45 | 20.58 | 21.48 |
Pivot Point | 20.15 | 20.15 | 20.00 | 20.07 | 20.15 |
Support 1 (S1) | 19.21 | 19.56 | 18.91 | 19.04 | 18.14 |
Support 2 (S2) | 18.61 | 19.20 | 18.53 | 18.01 | |
Support 3 (S3) | 17.67 | 18.61 | 17.89 | ||
Support 4 (S4) | 17.50 |